We are pleased to announce an expanded partnership with Cardiva, a Spanish-based medical device company. The partnership builds on an existing collaboration between AngioDynamics and Cardiva, which has seen the successful distribution of AngioDynamics’ vascular access portfolio in Spain and Portugal since 2012. The expanded partnership will now include AngioDynamics’ oncology portfolio, with the addition of the Italian market in the distribution agreement.
“We are thrilled to expand our collaboration with Cardiva and introduce our medical technology portfolio to even more patients across Europe” said Laura Piccinini, AngioDynamics’ International Senior Vice President/General Manager. “This partnership aligns with our strategy to broaden our international reach and accentuates our commitment to improving patient care around the world.”
The expanded partnership with Cardiva advances AngioDynamics’ Life Through Partnership program, which is designed to foster collaboration between medical device companies, healthcare providers, and key clinicians on an international scale.
Cardiva brings a wealth of experience and expertise to the partnership, with a focus on delivering innovative solutions to healthcare providers across Europe. By combining Cardiva’s distribution capabilities with AngioDynamics’ leading medical technologies, the partnership is well-positioned to meet the needs of patients and healthcare providers in the region.
“With this alliance, we are deepening our commitment to participate in the health of the future as a leading distributor of medical devices, making innovative solutions, such as those developed by AngioDynamics, available to healthcare professionals in the three countries (Spain, Italy, and Portugal) and, therefore, to a wide number of patients,” said Ignacio Vega, Chairman of Cardiva.
The partnership between AngioDynamics and Cardiva is an exciting development for the medical device industry and AngioDynamics’ Life Through Partnership initiative. By combining their strengths, the two companies are poised to make a difference in the lives of patients across Europe.